Conference Coverage

Weight-Loss Drug Hits Diabetes Target Trifecta


 

AT THE ANNUAL MEETING OF THE ENDOCRINE SOCIETY

Dr. Ryan reported serving as a scientific advisor to Vivus but holds no equity interest in the company.

Pages

Recommended Reading

Metformin May Reduce Liver Cancer Risk
MDedge Endocrinology
PSA May Be Unreliable in Type 1 Diabetes
MDedge Endocrinology
Despite Cardiac Concerns, FDA OKs Obesity Drug Lorcaserin
MDedge Endocrinology
GSK Pays $3 Billion to Settle Drug Promotion Charges
MDedge Endocrinology
Post-MI Rehospitalization Rate Has Not Declined Since 1987
MDedge Endocrinology
Tracking System Proposed for Medical Devices
MDedge Endocrinology
Type 2 Diabetes Re-Emerges After Bariatric Surgery
MDedge Endocrinology
Closed-Loop Insulin Boosts Overnight Control in Young Children
MDedge Endocrinology
Bariatric Surgery Yields Durable Results for Diabetic Nephropathy
MDedge Endocrinology
Newer Technologies May Improve Diabetes Control
MDedge Endocrinology